ASTS
AST SpaceMobile, Inc.
ASTS offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
TRT
Trio-Tech International
TRT has the edge over ASTS overall, supported by lower modeled downside and stronger fundamentals.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
TRT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Under pressure | |
| Strong |
TRT's revenue, profitability and balance sheet are currently healthy, but its cash flow is under pressure.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
TRT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $0.56 | -90% |
| Fair | 24x | $1.46 | -74% |
| Expensive | 47x | $2.81 | -50% |
| Current | 93x | $5.60 | — |
Historical ranges are pointers, not guarantees.
TRT's PE is in its expensive range at 93x.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
TRT Forward outlook
There aren't enough analyst estimates for TRT to show an outlook.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
TRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.06 | +100% |
| Q2 2026 | $0.00 | +$0.01 |
| Q1 2026 | $0.04 | +$0.05 |
| Q4 2025 | -$0.01 | -117% |
| Q3 2025 | $0.03 | -50% |
| Q2 2025 | -$0.01 | -108% |
| Q1 2025 | -$0.01 | -108% |
| Q4 2024 | $0.06 | -45% |
TRT has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over TRT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
TRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.9M | +29% |
| Q2 2026 | $14.9M | +40% |
| Q1 2026 | $16.5M | +124% |
| Q4 2025 | $15.6M | +82% |
| Q3 2025 | $15.5M | +58% |
| Q2 2025 | $10.7M | +9.5% |
| Q1 2025 | $7.4M | -29% |
| Q4 2024 | $8.6M | -29% |
TRT's revenue has grown year over year for six quarters in a row: $20M last quarter, up 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.3% | +6 points |
| Q2 2026 | -1.8% | -6.2 points |
| Q1 2026 | -0.5% | +4.2 points |
| Q4 2025 | 0.6% | +0.7 points |
| Q3 2025 | 0.3% | -1.1 points |
| Q2 2025 | 4.4% | +0.7 points |
| Q1 2025 | -4.7% | -5.2 points |
| Q4 2024 | 0% | -5.6 points |
TRT has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
TRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.1M | -567% |
| Q2 2026 | $244K | +$1.5M |
| Q1 2026 | $707K | +13% |
| Q4 2025 | -$152K | -108% |
| Q3 2025 | $887K | +$2.8M |
| Q2 2025 | -$1.2M | -$932K |
| Q1 2025 | $623K | -48% |
| Q2 2024 | -$289K | -123% |
TRT has the edge over ASTS on cash flow, with more consistent year-over-year improvement.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over TRT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
TRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +2.4M shares |
| 1 year | +31% | +2.7M shares |
| 3 years | +33% | +2.8M shares |
| 5 years | +42% | +3.4M shares |
TRT has 11M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $63,000 |
| Q2 2026 | — |
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TRT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.9x | Net Cash |
| Q2 2026 | -10.1x | Net Cash |
| Q1 2026 | -4.5x | Net Cash |
| Q4 2025 | -4.6x | Net Cash |
| Q3 2025 | -4.3x | Net Cash |
| Q2 2025 | -3.4x | Net Cash |
| Q1 2025 | -3.5x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
TRT has more cash than debt.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
TRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 7.5 | Oversold |
TRT's weekly RSI is 41 (neutral) and its Stochastic is 8 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
TRT PE vs Technology Sector
| Metric | TRT | Sector median | Relative |
|---|---|---|---|
| PE | 93x | 28x | 235% above |
| PE % | 88 | 35 | 53 pts above |
TRT is trading at 93x earnings, a 235% premium to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
TRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.40 | 3.7% above |
| 20 week MA | $8.43 | 34% below |
| 50 week MA | $8.47 | 34% below |
| 100 week MA | $5.72 | 2.1% below |
| 200 week MA | $4.29 | 31% above |
TRT has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
TRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.11 | $1.96 | -7.1% |
| 2021 | $1.96 | $6.27 | +220% |
| 2022 | $6.27 | $2.29 | -63% |
| 2023 | $2.29 | $2.54 | +11% |
| 2024 | $2.54 | $2.96 | +17% |
| 2025 | $2.96 | $7.00 | +136% |
| 2026 YTD | $7.00 | $5.60 | -20% |
TRT has the edge over ASTS on returns for 2026, with the stronger performance.